This again is in agreement with post hoc analyses from LEADER showing consistent MACE reduction regardless presence of chronic kidney disease27 and may represent an interesting alternative for patients with diabetic kidney disease, especially in view of plausible effects of GLP-1 use in retarding chronic kidney disease progression.28 This evidence concerns the gene GLP1R and chronic kidney disease.